Geneseeq Technology Inc.

Geneseeq is a research-driven company providing cutting-edge NGS technology to accelerate precision cancer care.

[Geneseeq Technology Inc. @GeneseeqInc]

#Announcing FDA has granted Geneseeq’s multi-cancer early detection solution, CanScan™, as Breakthrough Device Designation!

Read more about CanScan™: https://t.co/WO8Ji4bhi5

#NGS #oncology #cancer #Geneseeq #FDA

[Geneseeq Technology Inc. @GeneseeqInc]

#Announcing the National Medical Products Administration (#NMPA) has approved the Geneseeq Non-Small Cell Lung Cancer Tumor Mutational Burden (NSCLC TMB) Testing Kit!

Read more about the NSCLC TMB Test Kit: https://t.co/sRVgVe44J9

#NGS #oncology #cancer #Geneseeq

[Geneseeq Technology Inc. @GeneseeqInc]

#Announcing the CE-markings of our multi-cancer early detection kit and multi-cancer minimal residual disease kit!

https://t.co/bdjlkVvUFu

#cemark #MCED #MRD

[Geneseeq Technology Inc. @GeneseeqInc]

@Ramysaleh86 Thanks for sharing, Dr. Saleh!

[Geneseeq Technology Inc. @GeneseeqInc]

Our early cancer detection test displays high performance in differentiating early lung cancer patients from healthy individuals, and detecting Stage I lung cancers and tumors < 10mm! Learn more below.
@atscommunity #earlycancerdetection #lungcancer

https://t.co/0HVMxyjJKd

[Integrated DNA Technologies @idtdna]

TODAY at #ASHG22!

Haimeng Tang from @GeneseeqInc will give a presentation titled “ctDNA for minimal residual disease research by hybridization capture in resected cancer samples” at 3 pm in CoLab Theater 1. You won’t want to miss this!

@GeneticsSociety #IDT #IDTdna #ASHG2022

[Geneseeq Technology Inc. @GeneseeqInc]

A new oral presentation at #NCAM we worked on that assesses the efficacy and safety of osimertinib in #NSCLC patients with a sensitizing #EGFR mutation and T790M mutations, who have progressed following prior treatment with an approved EGFR #TKI.

https://t.co/xJPs5fVSST

[Geneseeq Technology Inc. @GeneseeqInc]

Happy to announce our partnership with Brazilian hospital Hospital de Base to build an #NGS cancer genomics lab in-house!
#cancertesting

https://t.co/v4aq3TphjF

[Geneseeq Technology Inc. @GeneseeqInc]

An overview of our high-performing early cancer detection program.
#precisiononcology #earlydetection

https://t.co/GGTObtDQIb

[Geneseeq Technology Inc. @GeneseeqInc]

Excited to be back at #ASCO22? We participated in the science behind 7 posters and 1 oral this year. Read more below and see you in Chicago! #precisiononcology

https://t.co/3OBxcHs9Ra

[Geneseeq Technology Inc. @GeneseeqInc]

A study using our comprehensive gene panel Geneseeqprime, provides an overview of kinase IGRs in a large #lungcancer cohort and examines real-world survival outcomes of patients.

https://t.co/VcZQmHNjUs

[Geneseeq Technology Inc. @GeneseeqInc]

Our DECIPHER study on #livercancer early detection was published in @HEP_Journal. The study demonstrates excellent performance in early #cancerscreening for liver cancer population while distinguishing ICC from HCC, using #liquidbiopsy.

https://t.co/uqFPzJ2Dqk

[Geneseeq Technology Inc. @GeneseeqInc]

Our DECIPHER early cancer detection program published a study in the @AASLDFoundation Hepatology journal on detecting liver cancer early.
In the study, the liver cancer screening tests demonstrated high sensitivity and specificity.
https://t.co/3R1ZRr4Lcw
#Cancer #earlydetection

[Geneseeq Technology Inc. @GeneseeqInc]

The study was conducted to demonstrate the status of perioperative ctDNA positivity is significantly associated with disease recurrence and long-term patient outcomes for resectable #NSCLC.

[Geneseeq Technology Inc. @GeneseeqInc]

A recent study we worked on shows that #ctDNA surveillance shows to predict tumor relapse earlier than traditional medical images with a lead time of 8.71 months!
#liquidbiopsy
https://t.co/4mjAvrrc1n

[Geneseeq Technology Inc. @GeneseeqInc]

Read about our newest study on using our comprehensive gene panel to characterize insightful tumor biomarkers and guide personalized adjuvant treatment for non-small-cell lung cancer patients!
@NaturePortfolio
#cancerresearch #NSCLC

https://t.co/WKMY5M5HAX

[Geneseeq Technology Inc. @GeneseeqInc]

Geneseeq and collaborators published a study on the genomic landscape of metastatic lung adenocarcinomas from clinical sequencing data of over 6000 samples!
#CancerResearch
https://t.co/iJUCuoyLLY

[Geneseeq Technology Inc. @GeneseeqInc]

Geneseeq and collaborators published a study with the largest early-stage colorectal cancer (stage 0/1) study cohort on #earlydetection.

The study yielded encouraging results!

Read more about the study below:
https://t.co/IdRmJDFSv5

[Geneseeq Technology Inc. @GeneseeqInc]

Our new study on repair-associated DNA polymerases in a cohort of 12,266 patients across 16 different tumor types demonstrates pathogenicity and additive prognostic value of polymerase and DDR pathway gene alterations.

https://t.co/KJakuLHY86
#cancerresearch #geneseeq

[Geneseeq Technology Inc. @GeneseeqInc]

Geneseeq will be presenting the results of a multi-center prospective study on the dynamic monitoring of ctDNA in children’s lymphoma at #SIOP2021!

Follow the conference for more details.
https://t.co/cYCy8u8ORw